|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1999-6-23
|
|
pubmed:abstractText |
The current health-care philosophy dictates that new therapies should always be evaluated for their economic impact. Along with acquisition cost, the cost of delivery, monitoring, adverse effects and treatment failure must also be considered when determining the total cost of therapy. These auxiliary costs can be significant and greatly alter the overall cost of a drug treatment. We conducted a prospective randomized study to evaluate the efficacy, safety and cost of vancomycin and teicoplanin therapy in patients with neutropenia, after the failure of empirical treatment with a combination of piperacillin/tazobactam and amikacin.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
84
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
231-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10189388-Amikacin,
pubmed-meshheading:10189388-Anti-Bacterial Agents,
pubmed-meshheading:10189388-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10189388-Bacterial Infections,
pubmed-meshheading:10189388-Blood Chemical Analysis,
pubmed-meshheading:10189388-Cost-Benefit Analysis,
pubmed-meshheading:10189388-Drug Costs,
pubmed-meshheading:10189388-Drug Resistance, Microbial,
pubmed-meshheading:10189388-Drug Therapy, Combination,
pubmed-meshheading:10189388-Female,
pubmed-meshheading:10189388-Hematologic Neoplasms,
pubmed-meshheading:10189388-Humans,
pubmed-meshheading:10189388-Male,
pubmed-meshheading:10189388-Middle Aged,
pubmed-meshheading:10189388-Neutropenia,
pubmed-meshheading:10189388-Penicillanic Acid,
pubmed-meshheading:10189388-Piperacillin,
pubmed-meshheading:10189388-Prospective Studies,
pubmed-meshheading:10189388-Safety,
pubmed-meshheading:10189388-Teicoplanin,
pubmed-meshheading:10189388-Treatment Failure,
pubmed-meshheading:10189388-Vancomycin
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
|
|
pubmed:affiliation |
Services of Hematology, University Hospital of Salamanca, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
